학술논문

The potential anti‐amyloidogenic candidate, SPA1413, for Alzheimer's disease.
Document Type
Article
Source
British Journal of Pharmacology. Mar2022, Vol. 179 Issue 5, p1033-1048. 16p. 1 Color Photograph, 1 Diagram, 1 Chart, 3 Graphs.
Subject
*ALZHEIMER'S disease
*AMYLOID plaque
*TRANSGENIC mice
*MICROGLIA
*HIGH throughput screening (Drug development)
*NEUROLOGICAL disorders
Language
ISSN
0007-1188
Abstract
Background and Purpose: Recently, isoflavone derivatives have been shown to have neuroprotective effects against neurological disorders. For instance, genistein attenuated the neuroinflammation and amyloid‐β accumulation in Alzheimer's disease animal models, suggesting the potential for use to prevent and treat Alzheimer's disease. Experimental Approach Here, 50 compounds, including isoflavone derivatives, were constructed and screened for the inhibitory effects on amyloid‐β42 fibrilization and oligomerization using the high‐throughput screening formats of thioflavin T assay and multimer detection system, respectively. The potential neuroprotective effect of t3‐(4‐hydroxyphenyl)‐2H‐chromen‐7‐ol (SPA1413), also known as dehydroequol, idronoxil or phenoxodiol, was evaluated in cells and in 5xFAD (B6SJL) transgenic mouse, a model of Alzheimer's disease. Key Results: SPA1413 had a potent inhibitory action on both amyloid‐β fibrilization and oligomerization. In the cellular assay, SPA1413 prevented amyloid‐β‐induced cytotoxicity and reduced neuroinflammation. Remarkably, the oral administration of SPA1413 ameliorated cognitive impairment, decreased amyloid‐β plaques and activated microglia in the brain of 5xFAD (B6SJL) transgenic mouse. Conclusion and Implications: Our results strongly support the repurposing of SPA1413, which has already received fast‐track status from the US Food and Drug Administration (FDA) for cancer treatment, for the treatment of Alzheimer's disease due to its potent anti‐amyloidogenic and anti‐neuroinflammatory actions. [ABSTRACT FROM AUTHOR]